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ABSTRACT 
The selective opioid mu receptor agonist dermorphin increased 
the locomotor activity of rats dose dependently at 1 0 to 1 00 
pmolfkg i.c.v. Respiratory rate, relative tidal volume and respi-
ratory minute volume also increased unrelated to changes in 
locomotor activity. Higher doses, on the other hand, produced 
catalepsy and respiratory depression. Pretreatment of the rats 
with the mu,-selective antagonist naloxonazine (10 mgfkg i.v.) 
blocked the stimulant locomotor and respiratory effects of low 
doses of dermorphin (1 0--1 00 pmolfkg), but potentiated the 
respiratory depressant effect of a high dose (1 0 nmolfkg) of 
Low doses of morphine or opioid peptides increase locomotor 
activity, whereas higher doses induce a cataleptic state, char-
acterized by the absence of movement and muscular rigidity 
(Tortella et al., 1978; Browne et al., 1979; Brady and Holtzman, 
91981; Havemann et al., 1983; Locke and Holtzman, 1986). 
Locke and Holtzman (1986) suggested that the depressant 
effect of opioids on locomotion might be mediated by mu-opioid 
and stimulant effect by delta-opioid receptors. In accordance 
with this concept, a potent and selective mu receptor agonist 
dermorphin (Rossi et al., 1986; Krumins, 1987) induced cata-
lepsy in the rat when administered i.c.v. at doses above 0.3 
nmol/kg (Paakkari and Feuerstein, 1988). 
The well known respiratory depressant effect of opioids (for 
review see Borison 1977) was also demonstrated for dermorphin 
in conscious rats (Paakkari et al., 1988). However, small doses 
of opioids can also induce an increase in ventilatory frequency 
(Hassen et al., 1982; Hurle et al., 1985) or mean instantaneous 
minute ventilation (Haddad et al., 1984; Schaeffer and Haddad, 
1985). 
The objective of the present study were to investigate 
whether low doses of dermorphin would also induce locomotor 
and respiratory stimulation and, if so, would the respiratory 
stimulation be secondary to the increase in locomotor activity. 
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dermorphin. The selective benzodiazepine antagonist flumazenil 
(5 mgfkg), which has been shown previously to antagonize 
catalepsy and respiratory depression produced by relatively high 
doses of dermorphin, did not antagonize the respiratory or 
locomotor stimulant effect of dermorphin. The data suggest that 
mu,-opioid receptors are responsible for the low dose stimulant 
effects of dermorphin on locomotor activity and respiration 
whereas mu2 receptors mediate the respiratory depressant effect 
of dermorphin. 
Furthermore, t.he role of mu1-opioid receptors in mediating the 
stimulatory effect of dermorphin was examined in rats treated 
with mu, receptor antagonist naloxonazine (Hahn et al., 1982). 
In addition, because the cataleptic and ventilatory depressant 
effect of dermorphin were antagonized by the benzodiazepine 
antagonist flumazenil (Ro 15-1788) (Paakkari and Feuerstein, 
1988; Paakkari et al., 1988), we found it of interest to examine 
whether the benzodiazepine/GABAergic system is also associ-
ated with dermorphin-induced locomotor and respiratory stim-
ulation. 
Methods 
Animals. Conscious male Sprague-dawley rats (250-330 g, Taconic 
Farms, Germantown, NY) were used. The animals received standard 
rat pellets and water ad libitum and were kept at 22•c and 12 hr/hr 
light dark cycle. 
Procedure for i.c. v. and i. v. injections. Rats were anesthetized 
with an i.m. injection of ketamine (130 mg/kg) and acepromazine (1.3 
mg/kg). A stainless-steel guide cannula was inserted stereotaxically 
(Oavid Kopf Instruments, Tujunga, CA) through the skull into tbe 
right lateral brain ventricle (i.c.v.) and fixed with glue (Eastman 910 
adhesive). Coordinates for the lateral ventricle were: AP, -0.8 mm and 
L, 1.2 mm (1967). After the operation the rats were allowed to recover 
for at least 3 days in single cages, with food and water ad libitum. A 
group of rats was implanted also with PE-50 tubing, filled with hepa-
rinized ( 100 U /ml) saline, in the extemal jugular vein for naloxonazine 
injections. The tubing was threads s.c. to the posterior neck, exited 
through a small incision, then cut to a lengtb of about 5 cm and sealed 
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by heat. The rats received a single i.v. injection of naloxonazine (10 
mg/kg, as the free base) or saline in a volume of 1 ml/kg 22 to 24 hr 
before dermorphin injections. 
On the day of the experiment, a 7.5 mm long 30 g cannula was 
inserted into the ventricular space through the guide cannula. The 
injection cannula was connected via polyethylene tubing to a Hamilton 
microliter syringe and the drug solution was injected over a period of 
20 sec in a volume of 10 "1. Each rat received a single dermorphin 
injection. The proper position of the i.c.v. cannula was ascertained at 
the end of the experiment by inspection of the brain ventricles after 
an injection of methylene blue (10 "1). 
Analgesia testing. Analgesia was measured by the tail-tlick test 
(O'Amour and Smith, 1941). A cut-off time of 12 sec was used to avoid 
tissue damage. Tail-flick response times were represented as percentage 
of maximum possible effect (% of MPE) according to the equation: 
% of MPE 
= post drug response latency - predrug response latency x 
100 
cut-off time - predrug response latency 
Locomotor activity monitoring. Locomotor activity was moni-
tored from 1 hr before until 2 hr after the drug administration. Digiscan 
Optical Digital Sensor Activity Monitors equipped with Datalogger 
8000 data collection devices (Omnitech Electronics Inc., Columbus, 
OH) were used to measure activity. The data was collected in counts 
per 5 min. During the experiment the animals were placed in the 
Oxymax Plexiglas chambers (see Respiratory recording) set inside the 
activity monitors, which made the simultaneous recording of respira-
tion and locomotor activity possible. 
Recording of respiration. Ventilation rate and relative ventilation 
tidal volume were monitored by the Oxymax 85 system (Columbus 
Instruments, Columbus, OH). The recording system consists of two 
sealed Plexiglas test chambers and one reference chamber (internal 
dimensions: 112 X 197 X 297 mm, volume: 6.551). Room air is pumped 
through each chamber at the constant rate of 2 liters/min. Recording 
of the respiration rate and relative tidal volume is based on the minute 
pressure changes in the chamber caused by the subject's breathing. 
The tidal volume information is presented as a series of pulses whose 
frequency ie proportional to the preeeure changee within the chamber. 
Totalizing these pulses with a computer allows for the presentation of 
an index tidal volume. Relative tidal volume and the calculated minute 
volume are therefore expressed in arbitrary units. 
The respiratory data were gathered at 2-min intervals for 60 min 
before and 60 to 120 min after the injections. The data were stored and 
processed by an IBM PC computer using the program Ostsquest 
provided by the manufacturer. Thereafter the output files were im-
ported into the spreadsheet (Framework II, Ashton-Tate) for calcula-
tion of maximum effects. The results are expressed as percentage of 
changes (means ± S.E.) from the base line during a 10-min time period, 
at 50 to 60 min after the injection, at which time the respiratory effects 
were maximal. The base lines were calculated from the values during 
the last 20 min before the drug injection. In all parameters the differ-
ences between the basal values of the groups were statistically not 
significant. Differences between means were analyzed with one-way 
analysis of variance followed by Tukey's test. For data with unequal 
variances the Kruskall-Wallis test followed by Mann-Whitney U tests 
were used. A significant difference was obtained at P < .05. 
Chemicala. Dermorphin (Sigma Chemical Co., St. Louis, MO) and 
naloxonazine (a generous gift from Dr. G. W. Pasternak, Memorial 
Sloan-Kettering Cancer Center, New York, NY) were dissolved in 0.9% 
saline, naloxonazine with a few drops of glacial acetic acid (final pH 
7.0). Flumazenil (gift from W. Haefely, Hoffman-La Roche Inc., Basel, 
Switzerland) was dissolved in 10% Emulphur 620 (GAF Corp., Grasseli, 
NJ)-ethanol mixture (1:1), warmed and sonicated immediately before 
administration. Flumazenil or saline were given i.p. in a volume of 1 
ml/kg, 20 min before the dermorphin injections. Naloxonazine (10 mg/ 
kg i.v.) was given 20 to 24 hr before dermorphin. 
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Results 
Locomotor effects of dermorphin. Dermorphin was 
tested at doses of 3, 10, 30 and 100 pmol/kg. The three highest 
doses increased locomotor activity, with 30 pmol/kg having the 
maximal effect (Fig. 1). lncreases in total (60 min) locomotor 
activity produced by 100 pmol/kg of dermorphin did not reach 
statistical significance (P < .19). However, the increase in 
locomotor activity during the first 10 min after the injection 
was significant (fig. 2). 
The spontaneaus locomotor activity of the resting ratswas 
near zero during the 10 min before drug injections. 
Respiratory effects of dermorphin. Low doses of der-
morphin (10 and 30 pmol/kg) increased the respiratory minute 
volume (fig. 3, lower panel). Respiration rate was increased 
significantly after the dose of 30 pmol/kg (fig. 3, upper panel). 
Higher doses (3 and 10 nmol/kg) decreased both respiration 
rate and minute volume. The corresponding changes in relative 
tidal volume were 3 ± 6% (saline), 6 ± 10% (3 pmol/kg), 86 ± 
74% (10 pmol/kg), 179 ± 128% (30 pmol/kg), -3 ± 9% (100 
pmol/kg), 23 ± 18 (3 nmol/kg) and -9 ± 7% (10 nmol/kg). The 
changes in relative tidal volume were not statistically signifi-
cant. 
Timecourse of locomotor and respiratory stimulation. 
The peak increase in locomotor activity was observed within 
15 min from the injection, whereas the respiratory stimulation 
was maximal 50 to 60 min after the injection (fig. 2). The effects 
of the dose of 100 pmol/kg at 10 min further shows that 
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Fig. 1. Locomotor activity (LA) of the rats after dermorphin (DM, 3-100 
pmolfkg i.c.v.), expressedas total counts from the 60-min period after 
drug injection. •p < .05; ••p < .01 (drug vs. solvent; n - 6 in each group). 
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Fig. 2. Time course of the changes in locomotor activity (LA) and 
respiratory minute volume (MV) after dermorphin (DM, 30 or 10 pmol/ 
kg). The counts show the difference between test and cantrot animals 
(the effect of solvent is subtracted from that of drug). •p < .05; ••p < 
.001; dependent t test, n = 6. 
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Fig. 3. Changes in ventilatory rate (VR, upper panel) and minute volume 
(MV, lower panel) after dermorphin (DM, 3 pmol-1 0 nmol/kg). •p < .05; 
••p < .001 ; n = 6 in each group. 
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Fig. 4. lnfluence of naloxonazine (NAZ, 10 mgjkg i.p.) and flumazenil 
(FLU, 5 mgjkg i.p.) pretreatments on the locomotor effect of dermorphin 
(DM, 30 pmol/kg). •p < .05; ••p < .001 when compared to solvent, +p 
< .05 when compared to DM (30 pmol/kg; n = 6 in each group). 
respiratory and locomotor stimulation were unrelated to each 
other, as the minute volume remained unchanged although 
locomotor activity increased significantly (fig. 2). 
Effects of dermorpbin after pretreatment with nalox-
onazine or fiumazenil. Naloxonazine (10 mg/kg i.v.) was 
given 20 to 24 hr before dermorphin. The dose of naloxonazine 
and the time for pretreatment was chosen to obtain maximal 
mu1-selectivity (Hahn et al., 1982; Ling et al., 1986). Naloxon-
azine antagonized both the locomotor (fig. 4) and respiratory 
(fig. 5) stimulation produced by dermorphin, 30 pmol/kg, the 
dose which had the maximal effect in the dose-response study. 
Flumazenil (5 mg/kg i.p. 20 min before dermorphin) did not 
significantly attenuate the locomotor and respiratory stimulant 
effects of dermorphin (figs. 4 and 5). 
To confirm the selectivity of naloxonazine antagonism on 
dermorphin-induced respiratory stimulation, one group of na-
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Fig. 5. lnfluence of naloxonazine (NAZ) and flumazenil (FLU) pretreat-
ments on the respiratory stimulant effect of dermorphin (DM, 30 pmol/ 
kg). ••p < .01 when compared to solvent; •p < .05 when compared to 
DM; n = 6 in each group. 
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Flg. 6. Potentiating effect of naloxonazine (NAZ) pretreatment on respi-
ratory depression induced by a high dose of dermorphin (DM, 10 nmol/ 
kg). •p < .05; ••p < .01 (DM vs. NAZ + DM, n = 6 in both groups). VR, 
ventilatary rate; TV, ventilatary tidal volume; MV, ventilatary minute 
volume; max. maximal . 
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Fig. 7. Analgesia induced by dermorphin (DM, 0.1 and 0.03 nmoljkg). 
The filled symbols represent the effect of the same doses of DM in 
naloxonazine (NAZ)-treated animals. •p < .05, n = 5 in all groups. MPE 
= maximum possible effect. 
loxonazine-treated ratswas given a respiratory depressant dose 
of dermorphin, 10 nmol/kg. Respiratory depressionwas poten-
tiated by naloxonazine pretreatment (fig. 6). 
Analgesie effect of dermorphin. Dermorphin, 0.03 and 
0.1 nmol/kg, induced analgesia, which was antagonized by 
naloxonazine (fig. 7). 
Discussion 
We have shown previously that the central administration 
of the heptapeptide dermorphin produces catalepsy and respi-
ratory depression at doses above 300 pmol/kg (Paakkari and 
Feuerstein, 1988; Paakkari et al., 1988). This study disclosed 
opposite effects of the same opioid, i.e., stimulation of locomo-
tor activity and respiration when lower doses, 10 to 100 pmol/ 
kg, were given. 
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The high potency of dennorphin (up to 5000 times more 
potent than morphine) described in analgesia studies and bioas-
says (Broccardo et al., 1981; Stevens and Yaksh, 1986), is 
evident also when the effects of opioids on locomotion are 
compared: the doses of morphine that in previous studies 
(Brady and Holtzman, 1981) induced maximallocomotor acti-
vation were 10,000-fold greater than the equipotent doses of 
dermorphin in our study. Even the corresponding doses of the 
specific mu agonist DAMGO were still 30 to 200-fold greater 
than those of dermorphin in our study (Locke and Holtzman, 
1987; Latimer et al., 1987). The outstanding potency of der-
morphin, which has been shown to have high selectivity and 
affinity for mu sites (about 3 times higher affinity than 
DAMGO; Krumins 1987), suggests that the locomotor activa-
tion is mediated via mu receptors. 
To our knowledge, the respiratory changes have not been 
measured in previous studies in which locomotor effects of 
opioids were investigated. It is conceivable that an increase in 
locomotor activity could subsequently Iead to an increase in 
respiration. Indeed, low doses of dermorphin consistently in-
creased respiratory rate and relative tidal volume. However, 
simultaneaus recording of respiration and locomotion revealed 
that Stimulation of respiration was unrelated to the increase in 
locomotor activity for the following reasons: first, the peak 
stimulation in locomotion was observed 10 to 15 min after 
dermorphin injection, whereas the maximum effect on respi-
rationwas reached 50 to 60 min after dermorphin administra-
tion; second, locomotor activity returned back to basal values 
at time of maximal respiratory stimulation; and third, the dose 
of 100 pmol/kg of dermorphin increased locomotor activity 
significantly without respiratory stimulation. 
Centrally administered mu-opioid agonists induced in most 
studies a respiratory depression (Holaday, 1982; Pfeiffer et al., 
1983; Pazos and Florez, 1983; Ward and Takemori, 1983; 
Morin-Surun et al., 1984), as did dermorphin in our previous 
study (Paakkari et al., 1988). However, local injections of small 
doses (3-30 pmol) of the mu-opioid agonist DAMGO into the 
nucleus tractus solitarius increased respiratory frequency, 
whereas a high dose (300 pmol) bad a depressant effect (Hassen 
et al., 1982). Furthermore, the mu agonists morphine (0.5 mg/ 
kg) and morphiceptin analog (Tyr-Pro-NMePhe-o-Pro-NH2, 
2-125 ~o~g/kg) increased instantaneous minute ventilation in 
conscious dogs upon intracisternal administration (Haddad et 
aL, 1984; Schaeffer and Haddad, 1985). Also, the mu-agonist 
o-Ala2-Me-Phe4-Met(O)ol5-enkephalin (FK-33824) and the 
delta-agonist o-Ala2-o-Leu5-enkephalin increased respiratory 
frequency and decreased tidal volume when applied to the 
ventral surface of the medulla oblongata of the anesthetized 
cat, whereas when applied to the rostro-dorsal surface of the 
pons they depressed respiratory frequency and increased tidal 
volume (Hurle et al., 1985). 
Pharmacological, biochemical and receptor binding studies 
support the presence of two subtypes of mu receptors: the mu1 
receptor which binds both opiates and most enkephalins with 
similar very high affinities (Kd values < 1 nM), and the m~ 
receptor which binds morphine preferentially (Wolozin and 
Pasternak, 1981; Nishimura et aL, 1983; Lutz et al., 1985; 
Goodman and Pasternak, 1985). The autoradiographic distri-
bution of mu1-sites to brain areas involved in antinociception 
(Goodrnan and Pasternak, 1985; Moskowitz and Goodman, 
1985a), and the correlation between the density of mu1 -sites 
and analgesic sensitivity in different mice strains (Moskowitz 
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and Goodman, 1985b), as weil as pharmacological studies with 
mu1-antagonists and delta/mu1-agonists (Pasternak et al., 1980; 
Zhang and Pasternak, 1981, 1988; Bodnar et al., 1988) imply 
that supraspinal opioid analgesia is mediated via mu1 receptors. 
The mu1 receptor antagonist naloxonazine selectively antago-
nized morphine analgesia without affecting the hypoxemia and 
hypercarbia produced by morphine (Ling et al., 1983, 1985), 
suggesting that the respiratory depressant effect of opioicls is 
mediated by m~ receptors. Along this hypothesis, it can be 
speculated that the stimulatory effects of the selective mu-
agonist dermorphin on respiration are mediated via mu1 recep-
tors. The aforementioned respiratory stimulation by small 
doses of mu-agonists or delta-agonists (Hassen et al., 1982; 
Schaeffer and Haddad, 1985; Hurle et al., 1985), known to bind 
to mu1 receptors with high affinity (W olozin and Pasternak, 
1981; Nishimura et aL, 1982; Lutz et al., 1985; Itzhak and 
Pasternak, 1987), could also be explained assuming that the 
small doses would bind to high affinity mu1 receptors only, 
leading to stimulation; at higher doses, the respiratory depres-
sant m~-effect would dominate. In our study dermorphin at 
the dose of 100 pmol/kg did neither stimulate nor depress 
respiration; this Iack of change from base line (fig. 3) may be 
due to a balance between the respiratory stimulant and depres-
sant effect of this dose. 
Stimulation of locomotor activity may similarly be a mu1 
receptor effect, as dermorphin does not bind to delta receptors, 
formerly proposed to mediate the opioid-induced increase in 
locomotor activity (Locke and Holtzman, 1986). In the present 
study naloxonazine did antagonize the respiratory and the 
locomotor stimulation by dermorphin, implying that these in-
deed were mu1 receptor-mediated effects. Latimer et aL (1987) 
also suggested recently that activation of dopamine neurons in 
the ventral tegmental region of the rat brain by morphine and 
enkephalin analogs, and the subsequent increase in motor 
activity, are mediated by mu receptors, perhaps the mu1-sub-
type. 
The analgesic effect of dermorphin was studied to character-
ize further its mu1 and m~ receptor-mediated actions. Der-
morphin-induced analgesia was antagonized by naloxonazine, 
corroborating the theory that mu1 receptors are involved in this 
effect. After the bighest dose of dermorpbin the naloxonazine-
treated animals were also clearly less cataleptic than in control 
group ( ordinary catalepsy tests were, however, not performed 
due to the recording of respiration), which is in concordance 
with the suggestion that catalepsy also is mediated via mu1 
receptors (Ling and Pasternak, 1982). 
To ascertain the selectivity of naloxonazine antagonism 
against mu1 receptors, we studied its influence on the respira-
tory depressant effect of a higher dose of dermorphin. lnstead 
of antagonism, there was a potentiation of respiratory depres-
sion. This is in accordance with the concept that m~ receptors 
mediate respiratory depression (Ling et al., 1985) and mu1 
receptors respiratory Stimulation: when the mu1 receptors were 
blocked by naloxonazine, dermorphin's depressant effect on the 
available m~ receptors was unopposed and potentiated. 
We have sbown previously that the benzodiazepine antago-
nist flumazenil attenuates the cataleptic (Paakkari and Feuer-
stein, 1988) and respiratory depressant (Paakkari et al., 1988) 
effect of dermorphin. lt also antagonizes the analgesic (Brady 
et al., 1984) and intestinal (Fioramonti et al., 1987) effects of 
centrally given mu-agonist opioids. However, the locomotor 
and respiratory stimulant effects of low doses of dermorphin 
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TABLE 1 
Putative receptcn lnvolved in verlous etfects of dermorphln 
NAZ, naloxonazine; FLU, ftumazeplne; BZ/GASA, benzodiazepine--y-aminobutyric 
ecid (GABA) receptor complex. 
Effect Dole 
Antagonz8d by 
Receplm 
NAZ FLU 
pmdf/cg 
i.c.v. 
Respiratory >10 Yes No Mu, 
Stimulation 
Locomotor >10 Yes No Mu1 
Stimulation 
Analgesia >30 Yes Yes Mu,; BZ/GABA 
Catalepsy >300 Yes Yes Mu,; BZ/GABA 
Respiratory >1000 No Yes Mu2; BZ/GABA 
depression 
were not antagonized by flumazenil. Hypothetically, this can 
be explained by postulating that very low concentrations of 
dermorphin would bind to high-affinity, naloxonazine-sensitive 
mu. receptors only; at higher analgesic, respiratory depressant 
and cataleptic doses it would interact with benzodiazepine/ 
GABAergic pathways (table 1), suggested to modulate various 
effects of opioids (Cooper et al., 1983; Naughton et al., 1985; 
Zambotti et al., 1987; Moreau and Pieri, 1988). 
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